Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


BlueSky Versatile 1

This article was originally published in The Gray Sheet

Executive Summary

Vacuum-assisted wound therapy device gains expanded FDA marketing go-ahead to include the claim "may promote wound healing," according to BlueSky. The device, which applies localized negative pressure to the wound bed, competes with Kinetic Concepts' Vacuum Assisted Closure system. The latter device generated $185.5 mil. in Q3 sales worldwide (1"The Gray Sheet" Nov. 8, 2004, p. 25). BlueSky expects the expanded claim will help the firm boost its 1%-5%, number-two market share. KCI filed a patent infringement suit against BlueSky in September 2003...

You may also be interested in...

Sales & Earnings In Brief

Zimmer/Centerpulse anniversary: Combined sales for Q3 are $700 mil., a 13% increase over the prior-year period, when the firms remained stand-alone entities. Little over a year after the Centerpulse acquisition, Zimmer CEO Ray Elliott stresses in an Oct. 25 call that an estimated loss of $50 mil. in sales dissynergies and distributor returns failed to hamper "sequentially solid" results in "global reconstructive procedure-and-mix growth." The company booked 16% growth in combined sales of reconstructive products in the third quarter, exactly level with Q2 figures. "If we adjust the second quarter for European distributor returns within the integration process, then [Q2] outgrew the first quarter, and a recently completed third quarter outgrew them both on a daily basis," he adds. To recover sales lost to dissynergies, Zimmer will implement "cross-training benefits which should accrue to our favor later in 2005." Elliott acknowledges that the firm's "toughest challenge" lies in Q4, because "to reach management's new range of $775 mil.-$780 mil. in sales, we now face a comparison to the fourth quarter of 2003 that had zero distributor returns." Zimmer's Q4 guidance is further challenged by a $9 mil. "overstatement" due to a miscalculation, the firm notes...

Sarepta Scores Another Remarkable Approval With Vyondys 53 For Duchenne

Formal dispute resolution was key element in four-month turnaround from rejection by US FDA to approval for golodirsen, the second Sarepta DMD drug to clear the agency after appearing to have minimal prospects.

Real-World Evidence Fails Another Test At US FDA

Correvio’s attempt to move vernakalant from 'clinical hold' to 'FDA approved' was a huge long shot. But the advisory committee vote – and looming FDA rejection – are another indication that real-world data is not a panacea.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts